Moderna falls up to 25% as elevated expectations overshadow positive cancer vaccine data
Moderna shares slid up to 25% on Thursday even though its cancer vaccine cut melanoma recurrence risk by 42% in certain patients.
59 min ago9 min read
Moderna
COVID Vaccine Maker Moderna Is S&P 500's Best Stock of 2026, Up 663%
Moderna is up 663% this year, the S&P 500's best performer, after its cancer vaccine trial with Merck passed a final-stage test.
10/10/2026 22:5810 min read